The Global Health Body Issues Alert Over Critical Lack of Obesity Medications

Under 10% of individuals who could benefit from weight-loss injections such as Wegovy are able to get them, states the global health agency as it releases its initial guidance on the drugs.

Given more than one billion people worldwide currently classified as obese, it is advocating for increased and just availability to this class of drugs.

Based on projections, over two billion could be obese by 2030 without intervention.

"Our latest guidelines acknowledges that excess weight is a long-term condition that can be addressed with holistic and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and logistical bottlenecks are significant obstacles to broad availability to the jabs that can assist patients in reducing significant body mass, says the organization.

Weight-Loss Drug Shortage

Even in the current best projected scenario, the supply of these medications might only reach about 100 million people – fewer than 10% of eligible patients, per the health organization.

The guideline calls on governments and firms to increase availability, through strategies like licensing agreements.

The intellectual property rights on semaglutide – the main component of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.

The Way Obesity Drugs Operate

The injections replicate a body's own hormone to delay gastric emptying, curb appetite and enhance satiety so users reduce food intake.

Patients commonly see weight reduction after several weeks of beginning the weekly injections.

Research suggests people may regain a significant portion after a year of halting the drug, when their typical appetite return.

To be overweight or obese raises your likelihood for contracting medical conditions, like diabetes, cardiovascular issues, stroke, and certain malignancies.

Obesity impacts individuals in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.